QTORIN rapamycin 3.9 percent gel

Microcystic lymphatic malformations

Manufacturer: Palvella Therapeutics
Regulatory submission: NDA submitted August 2026
Launch: Anticipated in the first half of 2027
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Dosing and administration

Dosage

1 evidence topic · 1 source

Dosing and administration: phase 3

“once-daily QTORIN™ rapamycin” (opens the source at this quote in a new tab)